Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial.
Chronic inflammation closely associates with obesity, metabolic syndrome, diabetes mellitus, and atherosclerosis. Evidence indicates that the immunomodulator pentraxin 3 (PTX3) may serve as a biomarker of these cardiometabolic disorders, but whether PTX3 predicts cardiovascular complications is unkn...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3976379?pdf=render |
| _version_ | 1811269164556353536 |
|---|---|
| author | Tetsuro Miyazaki Stephanie Chiuve Frank M Sacks Paul M Ridker Peter Libby Masanori Aikawa |
| author_facet | Tetsuro Miyazaki Stephanie Chiuve Frank M Sacks Paul M Ridker Peter Libby Masanori Aikawa |
| author_sort | Tetsuro Miyazaki |
| collection | DOAJ |
| description | Chronic inflammation closely associates with obesity, metabolic syndrome, diabetes mellitus, and atherosclerosis. Evidence indicates that the immunomodulator pentraxin 3 (PTX3) may serve as a biomarker of these cardiometabolic disorders, but whether PTX3 predicts cardiovascular complications is unknown. We examined the association of plasma PTX3 levels with recurrent coronary events via a prospective, nested, case-control design in the CARE trial. Among 4159 patients who had a prior myocardial infarction 3 to 20 months before enrollment and also had total cholesterol levels <240 mg/dL and LDL cholesterol levels between 115 and 175 mg/dL, we measured plasma PTX3 levels at baseline by high-sensitivity ELISA in 413 cases with recurrent myocardial infarction or coronary death during a 5-year follow-up period, and in 366 sex- and age-matched controls. Cases with recurrent coronary events and controls had similar PTX3 levels, and PTX3 did not predict recurrent coronary events - a finding that contrasts with that of C-reactive protein (CRP) and serum amyloid A (SAA) in this cohort. We then associated PTX3 levels with metabolic disorders. Low plasma PTX3 levels correlated with high body-mass index, waist circumference, and triglycerides; and with low HDL cholesterol. Overall, PTX3 levels correlated inversely with the number of metabolic syndrome components. PTX3 levels also correlated inversely with apoCIII and tissue plasminogen activator, but did not associate with CRP. Although the study further links low PTX3 levels with various features associated with metabolic syndrome, the results do not indicate that PTX3 can predict recurrent coronary events among MI survivors. |
| first_indexed | 2024-04-12T21:37:12Z |
| format | Article |
| id | doaj.art-cef81c18a1d1473ba515e6f9f0bf763d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T21:37:12Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-cef81c18a1d1473ba515e6f9f0bf763d2022-12-22T03:15:52ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0194e9407310.1371/journal.pone.0094073Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial.Tetsuro MiyazakiStephanie ChiuveFrank M SacksPaul M RidkerPeter LibbyMasanori AikawaChronic inflammation closely associates with obesity, metabolic syndrome, diabetes mellitus, and atherosclerosis. Evidence indicates that the immunomodulator pentraxin 3 (PTX3) may serve as a biomarker of these cardiometabolic disorders, but whether PTX3 predicts cardiovascular complications is unknown. We examined the association of plasma PTX3 levels with recurrent coronary events via a prospective, nested, case-control design in the CARE trial. Among 4159 patients who had a prior myocardial infarction 3 to 20 months before enrollment and also had total cholesterol levels <240 mg/dL and LDL cholesterol levels between 115 and 175 mg/dL, we measured plasma PTX3 levels at baseline by high-sensitivity ELISA in 413 cases with recurrent myocardial infarction or coronary death during a 5-year follow-up period, and in 366 sex- and age-matched controls. Cases with recurrent coronary events and controls had similar PTX3 levels, and PTX3 did not predict recurrent coronary events - a finding that contrasts with that of C-reactive protein (CRP) and serum amyloid A (SAA) in this cohort. We then associated PTX3 levels with metabolic disorders. Low plasma PTX3 levels correlated with high body-mass index, waist circumference, and triglycerides; and with low HDL cholesterol. Overall, PTX3 levels correlated inversely with the number of metabolic syndrome components. PTX3 levels also correlated inversely with apoCIII and tissue plasminogen activator, but did not associate with CRP. Although the study further links low PTX3 levels with various features associated with metabolic syndrome, the results do not indicate that PTX3 can predict recurrent coronary events among MI survivors.http://europepmc.org/articles/PMC3976379?pdf=render |
| spellingShingle | Tetsuro Miyazaki Stephanie Chiuve Frank M Sacks Paul M Ridker Peter Libby Masanori Aikawa Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. PLoS ONE |
| title | Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. |
| title_full | Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. |
| title_fullStr | Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. |
| title_full_unstemmed | Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. |
| title_short | Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. |
| title_sort | plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the care trial |
| url | http://europepmc.org/articles/PMC3976379?pdf=render |
| work_keys_str_mv | AT tetsuromiyazaki plasmapentraxin3levelsdonotpredictcoronaryeventsbutreflectmetabolicdisordersinpatientswithcoronaryarterydiseaseinthecaretrial AT stephaniechiuve plasmapentraxin3levelsdonotpredictcoronaryeventsbutreflectmetabolicdisordersinpatientswithcoronaryarterydiseaseinthecaretrial AT frankmsacks plasmapentraxin3levelsdonotpredictcoronaryeventsbutreflectmetabolicdisordersinpatientswithcoronaryarterydiseaseinthecaretrial AT paulmridker plasmapentraxin3levelsdonotpredictcoronaryeventsbutreflectmetabolicdisordersinpatientswithcoronaryarterydiseaseinthecaretrial AT peterlibby plasmapentraxin3levelsdonotpredictcoronaryeventsbutreflectmetabolicdisordersinpatientswithcoronaryarterydiseaseinthecaretrial AT masanoriaikawa plasmapentraxin3levelsdonotpredictcoronaryeventsbutreflectmetabolicdisordersinpatientswithcoronaryarterydiseaseinthecaretrial |